Q3 2024 Upcoming FDA Decision Dates (PDUFAs)

Q3 2024 Upcoming FDA Decision Dates (PDUFAs)

As we move into the second half of 2024, following a hopeful uptick for the biotech industry in the first two quarters, it’s more important than ever to stay on top of the news in this ever-evolving industry. Some of the most crucial developments to keep up with are the approaching FDA approval dates, which provide insight into the industry’s outlook for the rest of the year.

Read on for a rundown of the FDA’s upcoming decision dates for new drug approvals in the third quarter of 2024.

 
DATE COMPANY NAME DRUG NAME USE/THERAPEUTIC AREA
01/3/2024 Checkpoint Therapeutics Cosibelimab Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
01/5/2024 Novan Berdazimer Gel, 10.3% Molluscum Contagiosum
01/12/2024 Astellas Olbetuximab Gastroesophageal junction (GEJ) adenocarcinoma
01/12/2024 Astellas Pharma Zolbetuximab Gastric Cancer
01/13/2024 GC Biopharma GC5107B Primary Humoral Immunodeficiency (PI)
01/17/2024 Merck WELIREG (belzutifan) Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
01/20/2024 Merck Keytruda (pembrolizumab) Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
01/20/2024 Theratechnologies Tesamorelin F8 Formulation Reduction of excess abdominal fat in adults with HIV who have lipodystrophy
01/23/2024 Heron Therapeutics ZYNRELEF (bupivacaine and meloxicam) Post-Operative Pain
01/24/2024 Liquidia Corporation Yutrepia (treprostinil) Pulmonary Arterial Hypertension (PAH); Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD)
01/26/2024 Defender Pharmaceuticals scopolamine (DPI-386) Motion Sickness
01/31/2024 Sanofi and Regeneron Dupixent (dupilumab) Eosinophilic esophagitis (EoE)
01/31/2024 Vyluma NVK002 Myopia
02/13/2024 Ipsen Onivyde (irinotecan liposome injection) Metastatic pancreatic ductal adenocarcinoma
02/22/2024 Venatorx Pharmaceuticals cefepime-taniborbactam Complicated Urinary Tract Infections (cUTI), including Pyelonephritis
02/24/2024 Iovance Biotherapeutics Lifileucel Advanced Melanoma
02/24/2024 Alvotech AVT02 Inflammatory diseases including rheumatoid arthritis
02/26/2024 Minerva Neurosciences Roluperidone Schizophrenia- Negative Symptoms
03/4/2024 Eyenovia APP13007 Post-operative inflammation and pain following ocular surgery
03/4/2024 Vanda Pharmaceuticals HETLIOZ (tasimelteon) Non-24-Hour Sleep-Wake Disorder (Non-24) in adults
03/8/2024 Viatris and Mapi Pharma Copaxone (Glatiramer Acetate Depot) Relapsed forms of multiple sclerosis (MS)
03/13/2024 Mirum Pharmaceuticals Livmarli (maralixibat) Cholestatic pruritus in patients with progressive familial intrahepatic cholestasis (PFIC)
03/14/2024 Madrigal Pharmaceuticals Resmetirom Nonalcoholic steatohepatitis (NASH)
03/14/2024 Bristol Myers Squibb Breyanzi (lisocabtagene maraleucel) Relapsed/refractory large B-cell lymphoma (LBCL)
03/16/2024 Optinose XHANCE Chronic rhinosinusitis with nasal polyps (CRSwNP)
03/18/2024 Orchard Therapeutics OTL-200 Metachromatic leukodystrophy (MLD)
03/21/2024 Italfarmaco Group Givinostat Duchenne Muscular Dystrophy (DMD)
03/23/2024 Incyte ruxolitinib myelofibrosis, polycythemia vera, and graft vs. host disease (GVHD)
03/26/2024 Merck Sotatercept Pulmonary arterial hypertension (PAH)
03/27/2024 Akebia Therapeutics Vadadustat Anemia in patients with CKD undergoing dialysis
03/27/2024 Esperion NEXLETOL (bempedoic acid) Lowers the level of cholesterol in the blood
03/30/2024 Vertex and CRISPR Therapeutics Casgevy (exagamglogene autotemcel) Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
03/31/2024 Rocket Pharmaceuticals RP-L201 (marnetegragene autotemcel) Leukocyte adhesion deficiency-I (LAD-I)
03/31/2024 Regeneron Pharmaceuticals Odronextamab (REGN1979) Relapsed/refractory follicular lymphoma or relapsed/refractory diffuse large B-cell lymphoma (DLBCL)
04/01/2024 AstraZeneca Voydeya (danicopan) Extravascular hemolysis in adults with paroxysmal nocturnal hemoglobinuria (PNH)
04/02/2024 Vanda Pharmaceuticals Fanapt Manic or mixed episodes associated with bipolar I disorder in adults
04/03/2024 Basilea Pharmaceutica AG ZEVTERA (Ceftobiprole) SAB infections and ABSSSI in adults and for CABP in adults and pediatric patients
04/04/2024 Bristol Myers Squibb & 2seventy Bio Abecma (idecabtagene vicleucel; ide-cel) Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
04/05/2024 Janssen & Legend Biotech Carvykti (ciltacabtagene autoleucel; cilta-cel) Relapsed or refractory multiple myeloma
04/05/2024 Bristol Myers Squibb Opdivo (nivolumab) Unresectable or metastatic urothelial carcinoma
04/05/2024 Supernus Pharmaceuticals SPN-830 Motor fluctuations (OFF episodes) in Parkinson’s disease
04/05/2024 AbbVie/Immunogen ELAHERE Platinum-Resistant Ovarian Cancer
04/23/2024 ImmunityBio N-803 BCG-unresponsive non-muscle invasive bladder carcinoma (NMIBC)
04/28/2024 Aquestive Therapeutics Libervant (diazepam) Buccal Film Seizure clusters in patients between two and five years of age
04/29/2024 PharmaTher KETARX (Ketamine) Mental health, neurological and pain disorders
04/30/2024 Day One Biopharmaceuticals Tovorafenib Relapsed or progressive pediatric low-grade glioma (pLGG)
04/30/2024 X4 Pharmaceuticals Mavorixafor WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome
04/30/2024 Neurocrine Biosciences Inc INGREZZA (valbenazine) Tardive dyskinesia and chorea associated with Huntington’s disease
05/09/2024 Astellas Pharma Inc. PADCEV (enfortumab vedotin-ejfv) Advanced Bladder Cancer
05/09/2024 Merck KEYTRUDA (pembrolizumab) Plus Padcev (enfortumab vedotin-ejfv) Locally advanced or metastatic urothelia
05/09/2024 Pfizer & GENMAB Tivdak Recurrent or Metastatic Cervical Cancer
05/13/2024 Dynavax Technologies Corp HEPLISAV-B Infection caused by all known subtypes of hepatitis B virus
05/14/2024 Ascendis Pharma TransCon PTH (Palopegteriparatide) Hypoparathyroidism
05/23/2024 Bristol Myers Squibb Breyanzi (lisocabtagene maraleucel) Relapsed or refractory follicular lymphoma (FL)
05/25/2024 Abeona Therapeutics Pz-cel Recessive dystrophic epidermolysis bullosa
05/30/2024 Daiichi Sankyo & AstraZeneca Enhertu (trastuzumab deruxtecan) Unresectable or Metastatic HER2 Positive Solid Tumors
05/31/2024 Bristol Myers Squibb Breyanzi (lisocabtagene maraleucel) Relapsed or refractory mantle cell lymphoma (MCL)
06/04/2024 Catalyst Pharmaceutical Firdapse (amifampridine) Lambert-Eaton myasthenic syndrome (“LEMS”)
06/07/2024 GSK AREXVY (RSV Vaccine) Prevention of RSV disease in adults aged 50-59 at increased risk
06/10/2024 Ipsen and GENFIT Elafibranor Rare cholestatic liver disease, primary biliary cholangitis (PBC)
06/12/2024 Amgen Tarlatamab Advanced small cell lung cancer (SCLC)
06/15/2024 Bristol-Myers Squibb Augtyro (repotrectinib) NTRK-Positive Locally Advanced or Metastatic Solid Tumors
06/16/2024 Geron Corporation Imetelstat Lower risk myelodysplastic syndromes (MDS)
06/17/2024 Merck & Ligand Pharmaceuticals V116 Prevent of invasive pneumococcal disease and pneumococcal pneumonia
06/21/2024 Sarepta Therapeutics ELEVIDYS (delandistrogene moxeparvovec-rokl) Duchenne muscular dystrophy (DMD)
06/21/2024 Argenx VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Chronic inflammatory demyelinating polyneuropathy (CIDP)
06/21/2024 Merck & Co Inc. KEYTRUDA (pembrolizumab) Advanced endometrial cancer
06/21/2024 Bristol-Myers Squibb KRAZATI (adagrasib) KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC)
06/21/2024 Harmony Biosciences WAKIX (pitolisant) Excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy
06/26/2024 Merck & Daiichi Sankyo Patritumab deruxtecan (HER3-DXd) Locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with two or more systemic therapies
06/26/2024 Verona Pharma plc Ensifentrine Asthma and chronic obstructive pulmonary disease (COPD)
06/27/2024 Sanofi Dupixent (dupilumab) Chronic obstructive pulmonary disease (COPD) with type 2 inflammation
06/28/2024 AbbVie & GENMAB EPKINLY (Epcoritamab-bysp) Elapsed or Refractory Follicular Lymphoma (FL)
06/30/2024 Rocket Pharmaceuticals RP-L201 (marnetegragene autotemcel) Leukocyte adhesion deficiency-I (LAD-I)
07/7/2024 Arcutis Biotherapeutics Inc. Roflumilast Cream 0.15% Atopic Dermatitis in Adults and Children Down to Age 6
07/15/2024 Orexo AB OX124 opioid overdose
07/19/2024 Phathom Pharmaceuticals Inc VOQUEZNA (vonoprazan) Tablets Heartburn associated with Non-Erosive GERD
07/25/2024 AstraZeneca IMFINZI Resectable non-small cell lung cancer
07/27/2024 Alpha Cognition Inc. ALPHA-1062 Mild-to-moderate Alzheimer’s disease in U.S.
07/31/2024 Xspray Pharma Dasynoc (dasatinib amorphous) Chronic myeloid leukemia (CML)
08/4/2024 Adaptimmune Therapeutics Afami-cel Advanced synovial sarcoma
08/10/2024 Humacyte, Inc. Human Acellular Vessel Vascular trauma
08/13/2024 Citius Pharmaceuticals LYMPHIR (denileukin diftitox) Relapsed or refractory cutaneous T-cell lymphoma (CTCL)
08/14/2024 Ascendis Pharma TransCon PTH (palopegteriparatide) Hypoparathyroidism
08/14/2024 Gilead Sciences Seladelpar Primary Biliary Cholangitis (PBC)
08/20/2024 Royal Pharma vorasidenib IDH-mutant glioma
08/22/2024 Regeneron Pharmaceuticals Linvoseltamab Relapsed/refractory (R/R) multiple myeloma (MM)
08/23/2024 GSK Jemperli (dostarlimab) Primary advanced or recurrent endometrial cancer
08/28/2024 Incyte Corporation / Syndax Pharmaceuticals Axatilimab Chronic Graft-Versus-Host Disease
09/5/2024 Travere Therapeutics / Ligand Pharmaceuticals Filspari (sparsentan) IgA Nephropathy
09/7/2024 AVADEL PHARMACEUTICALS LUMRYZ Cataplexy or EDS in the pediatric narcolepsy population
09/18/2024 VANDA PHARMACEUTICALS Tradipitant Gastroparesis
09/21/2024 Zevra Therapeutics / XOMA Corporation Arimoclomol Niemann-Pick disease type C
09/23/2024 Heron Therapeutics ZYNRELEF Instillation to produce postsurgical analgesia for up to 72 hours after soft tissue and orthopedic procedures
09/24/2024 IntraBio IB1001 (N-acetyl-L-leucine) Niemann-Pick disease Type C (NPC)
09/25/2024 Merck KEYTRUDA (pembrolizumab) Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma
09/26/2024 Syndax Pharmaceuticals Revumenib Relapsed or refractory (R/R) KMT2A-rearranged (KMT2Ar) acute leukemia
09/26/2024 Bristol-Myers Squibb KarXT Schizophrenia in adults
09/27/2024 Regeneron Pharmaceuticals / Sanofi Dupixent Chronic obstructive pulmonary disease (COPD) with type 2 inflammation
09/27/2024 Sanofi Sarclisa (isatuximab-irfc) in combination with bortezomib, lenalidomide, and dexamethasone treatment of transplant-ineligible newly diagnosed multiple myeloma
Q2 2024 Pfizer Fidanacogene elaparvovec Hemophilia B
Q2 2024 BeiGene Beukina (zanubrutinib) Relapsed or refractory follicular lymphoma
Q2 2024 Roche XOLAIR (omalizumab) Asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), chronic spontaneous urticaria (CSU)
Q2 2024 AstraZeneca TAGRISSO (osimertinib) Non-small cell lung cancer (NSCLC)
Q2 2024 AstraZeneca FluMist Quadrivalent Active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine.
Adapting to Changing Candidate Needs in 2024

Adapting to Changing Candidate Needs in 2024

Author:  Tara Smylie

As we approach the summer of 2024, the biotech job market continues to evolve at lightning speed. To attract top talent in an ever-changing hiring landscape, you need to stay ahead of the curve and understand exactly what the candidates of today are looking for. So, how have candidate’s needs and wants changed since 2023?

The Biotech Skills Gap

For several years now, there has been a growing gap in biotech skills – or in other words, a shortage of candidates who are trained to fill the roles many companies are scrambling to fill in 2024. One way to tackle this gap: teaming up with educational institutions training the employee soon to enter the workforce. By working together to develop educational materials and curricula, you can ensure that students are getting the skills they need to succeed in the real world.

Another effective way to bridge the biotech skills gap is by implementing in-house training programs. By investing in the professional development of your existing workforce, you can upskill employees and prepare them for the evolving demands of the biotech industry. In-house training programs can be tailored to the specific needs of your company, ensuring that employees are equipped with the particular skills required to excel in their roles.

What Attracts the Best Employees in 2024?

It’s 2024, and flexibility is key: candidates want the freedom to set their own schedules. Now, that doesn’t mean letting them work whenever they want, but being open to flexible working hours is a huge perk. After all, in a world where employees are often spread across various time zones, a rigid schedule just doesn’t cut it anymore.

At least some leeway around remote work is almost a must for the modern-day workplace. That said, it’s important to keep things personal. Embrace the digital age by conducting Zoom interviews, using online questionnaires, and giving virtual workplace tours. These digital tools not only make the hiring process more efficient, but also help candidates get a feel for your company culture – even if they’re miles away.

Lastly, don’t forget about branding! Working with a recruiter to develop a strong company message can make you more appealing to top candidates. Your employer brand extends beyond just your company website and social media presence, but to every touchpoint candidates have with your organization, from the recruitment process to onboarding and beyond. A strong employer brand can help you attract passive candidates who may not be actively looking for a new job but are drawn to your company’s reputation as an employer of choice.

Workplace Culture

In 2024, a positive workplace culture is not just a nice-to-have; it’s a must-have. Candidates are actively seeking out environments that prioritize collaboration, support, and camaraderie. They want to work in a place where they feel valued and appreciated, where they can contribute to a shared vision and be part of a team that feels like family.

But what exactly does a positive workplace culture look like in 2024? For starters, it means valuing teamwork above all else. Candidates want to work in an environment where everyone is encouraged to share ideas, collaborate on projects, and support one another. Whether it’s brainstorming sessions, cross-functional team projects, or company-wide initiatives, candidates want to feel like they are part of something bigger than themselves.

Additionally, candidates are drawn to companies that know how to have fun. In 2024, employees want to work for a company that knows how to strike the right balance between work and play. Whether it’s hosting team-building activities, organizing company-wide events, or simply celebrating milestones together, candidates want to work for a company that doesn’t shy away from a little fun. After all, a happy team is a productive team!

Making Your Offer Competitive

With so many companies competing for the best employees, it can be tough to stand out. But don’t worry – we’ve got your back! If you’re looking to fill a role with a highly qualified candidate, Sci.bio’s recruitment services can help. We know that no two clients are the same, so we provide customized recruiting support that adapts to a given client’s structure and needs and have placed successful candidates with a variety of companies. Please contact us to connect with a recruiter and discuss your needs, and follow us on LinkedIn to stay up to date.

Related Blogs:
1. Job Perks that Matter Most to Candidates
2. An Offer They Can’t Refuse
3. Struggling To Fill A Job Vacancy?

References
1. The Future of Biotech Talent Acquisition: Trends and Predictions for 2024
2. Top 5 Job Seekers’ Expectations in 2024
3. Best Practices in Recruiting

Q2 2024 Upcoming FDA Decision Dates (PDUFAs)

Q2 2024 Upcoming FDA Decision Dates (PDUFAs)

When you work in an industry as rapidly changing as biotechnology, it’s crucial to stay up to date. Awareness of the FDA’s new drug approval dates is especially crucial: the decisions put forth on these dates can significantly affect the outlook of the companies involved, and these ramifications often reverberate through the industry as a whole.

Read on for a rundown of the FDA’s upcoming decision dates for new drug approvals in the first quarter of 2024.

DATE COMPANY NAME DRUG NAME USE/THERAPEUTIC AREA
04/01/2024 AstraZeneca Voydeya (danicopan) Extravascular hemolysis in adults with paroxysmal nocturnal hemoglobinuria (PNH)
04/02/2024 Vanda Pharmaceuticals Fanapt Manic or mixed episodes associated with bipolar I disorder in adults
04/03/2024 Basilea Pharmaceutica AG ZEVTERA (Ceftobiprole) SAB infections and ABSSSI in adults and for CABP in adults and pediatric patients
04/04/2024 Bristol Myers Squibb & 2seventy Bio Abecma (idecabtagene vicleucel; ide-cel) Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
04/05/2024 Janssen & Legend Biotech Carvykti (ciltacabtagene autoleucel; cilta-cel) Relapsed or refractory multiple myeloma
04/05/2024 Bristol Myers Squibb Opdivo (nivolumab) Unresectable or metastatic urothelial carcinoma
04/05/2024 Supernus Pharmaceuticals SPN-830 Motor fluctuations (OFF episodes) in Parkinson’s disease
04/05/2024 AbbVie/Immunogen ELAHERE Platinum-Resistant Ovarian Cancer
04/23/2024 ImmunityBio N-803 BCG-unresponsive non-muscle invasive bladder carcinoma (NMIBC)
04/28/2024 Aquestive Therapeutics Libervant (diazepam) Buccal Film Seizure clusters in patients between two and five years of age
04/29/2024 PharmaTher KETARX (Ketamine) Mental health, neurological and pain disorders
04/30/2024 Day One Biopharmaceuticals Tovorafenib Relapsed or progressive pediatric low-grade glioma (pLGG)
04/30/2024 X4 Pharmaceuticals Mavorixafor WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome
04/30/2024 Neurocrine Biosciences Inc INGREZZA (valbenazine) Tardive dyskinesia and chorea associated with Huntington’s disease
05/09/2024 Astellas Pharma Inc. PADCEV (enfortumab vedotin-ejfv) Advanced Bladder Cancer
05/09/2024 Merck KEYTRUDA (pembrolizumab) Plus Padcev (enfortumab vedotin-ejfv) Locally advanced or metastatic urothelia
05/09/2024 Pfizer & GENMAB Tivdak Recurrent or Metastatic Cervical Cancer
05/13/2024 Dynavax Technologies Corp HEPLISAV-B Infection caused by all known subtypes of hepatitis B virus
05/14/2024 Ascendis Pharma TransCon PTH (Palopegteriparatide) Hypoparathyroidism
05/23/2024 Bristol Myers Squibb Breyanzi (lisocabtagene maraleucel) Relapsed or refractory follicular lymphoma (FL)
05/25/2024 Abeona Therapeutics Pz-cel Recessive dystrophic epidermolysis bullosa
05/30/2024 Daiichi Sankyo & AstraZeneca Enhertu (trastuzumab deruxtecan) Unresectable or Metastatic HER2 Positive Solid Tumors
05/31/2024 Bristol Myers Squibb Breyanzi (lisocabtagene maraleucel) Relapsed or refractory mantle cell lymphoma (MCL)
06/04/2024 Catalyst Pharmaceutical Firdapse (amifampridine) Lambert-Eaton myasthenic syndrome (“LEMS”)
06/07/2024 GSK AREXVY (RSV Vaccine) Prevention of RSV disease in adults aged 50-59 at increased risk
06/10/2024 Ipsen and GENFIT Elafibranor Rare cholestatic liver disease, primary biliary cholangitis (PBC)
06/12/2024 Amgen Tarlatamab Advanced small cell lung cancer (SCLC)
06/15/2024 Bristol-Myers Squibb Augtyro (repotrectinib) NTRK-Positive Locally Advanced or Metastatic Solid Tumors
06/16/2024 Geron Corporation Imetelstat Lower risk myelodysplastic syndromes (MDS)
06/17/2024 Merck & Ligand Pharmaceuticals V116 Prevent of invasive pneumococcal disease and pneumococcal pneumonia
06/21/2024 Sarepta Therapeutics ELEVIDYS (delandistrogene moxeparvovec-rokl) Duchenne muscular dystrophy (DMD)
06/21/2024 Argenx VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Chronic inflammatory demyelinating polyneuropathy (CIDP)
06/21/2024 Merck & Co Inc. KEYTRUDA (pembrolizumab) Advanced endometrial cancer
06/21/2024 Bristol-Myers Squibb KRAZATI (adagrasib) KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC)
06/21/2024 Harmony Biosciences WAKIX (pitolisant) Excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy
06/26/2024 Merck & Daiichi Sankyo Patritumab deruxtecan (HER3-DXd) Locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with two or more systemic therapies
06/26/2024 Verona Pharma plc Ensifentrine Asthma and chronic obstructive pulmonary disease (COPD)
06/27/2024 Sanofi Dupixent (dupilumab) Chronic obstructive pulmonary disease (COPD) with type 2 inflammation
06/28/2024 AbbVie & GENMAB EPKINLY (Epcoritamab-bysp) Elapsed or Refractory Follicular Lymphoma (FL)
06/30/2024 Rocket Pharmaceuticals RP-L201 (marnetegragene autotemcel) Leukocyte adhesion deficiency-I (LAD-I)
Q2 2024 Pfizer Fidanacogene elaparvovec Hemophilia B
The Collapse of Internal Talent Acquisition Functions – Challenges and Solutions

The Collapse of Internal Talent Acquisition Functions – Challenges and Solutions

Author:  Tara Smylie

Picture this: You’re a biotech company on the cutting edge of innovation, racing against the clock to develop life-changing therapies and technologies. But there’s a problem lurking in the shadows – your internal talent acquisition function is crumbling under the weight of escalating costs, a scarcity of specialized training, and pressing time constraints.

Sound familiar? You’re not alone. In the fast-paced world of life sciences and biotech, many organizations’ internal talent acquisition processes are simply not keeping up with their recruitment needs. But fear not: in this blog post, we’ll explore the challenges plaguing internal talent acquisition teams – and uncover effective solutions to help you navigate the turbulent HR landscape of the modern day.

Internal Talent Acquisition in the Life Sciences: How’s it Going?

The life sciences and biotech industries are burgeoning with new discoveries and advancements. As a result, the demand for skilled professionals in such areas is soaring, and talent acquisition in these fields is struggling to keep up. In the face of fierce competition for top talent and rapidly evolving industry requirements, companies are facing an uphill battle to secure candidates that truly suit their needs.

Three Major Challenges to Internal HR Teams in 2024

Internal talent acquisition teams in the life sciences and biotech sectors are grappling with a myriad of challenges, including:

  • Escalating Costs: Recruiting and hiring top talent can be a costly endeavor, particularly for specialized roles in the life sciences. Internal talent acquisition teams often find themselves burdened with rising expenses from sourcing, screening, and onboarding new candidates.
  • Skills Shortages: Rapid technological advancements and shifting industry demands have created a skills gap, leaving internal recruiters scrambling to find candidates with the right expertise. Unfortunately, a shortage of qualified talent can impede organizational growth and innovation.
  • Time Constraints: In a competitive job market, time is of the essence. Internal talent acquisition functions must contend with tight deadlines and high-pressure environments, leaving little room for error or delays in the recruitment process.

External Recruitment Agencies: to Use or Not to Use?

Amidst the many challenges to the modern internal hiring process, many life science and biotech companies are turning to external recruitment agencies. Here are some key benefits of partnering with an external agency:

  • Specialized Expertise: External recruitment agencies have in-depth knowledge of the life sciences industry and its unique talent landscape. They can leverage this expertise to identify, attract, and secure top talent that aligns with your organization’s specific objectives.
  • Broader Candidate Reach: External agencies have extensive networks and resources for sourcing candidates, both locally and globally. This broader reach allows them to tap into a diverse pool of talent, including passive candidates who are not actively seeking new opportunities.
  • Cost Efficiency: Contrary to popular belief, partnering with an external recruitment agency can be a cost-effective solution. By outsourcing recruitment activities, companies can reduce overhead costs associated with internal hiring processes, such as advertising, screening, and training.

Keys to a Seamless Recruiting Experience

Given the mushrooming demand for talent in the life sciences and biotech fields and the increasingly complex STEM hiring landscape, internal talent acquisition teams are finding it challenging to keep up. The good news: by understanding these challenges and exploring effective responses, organizations can navigate the recruitment landscape with confidence. Whether it’s leveraging the expertise of external recruitment agencies or implementing innovative hiring strategies, investing in talent acquisition is essential for driving long-term success in an increasingly competitive market.

If you’re looking to fill a role with a highly qualified candidate, Sci.bio’s recruitment services can help. We know that no two clients are the same.  So we provide customized recruiting support that adapts to a given client’s structure and needs and have placed successful candidates with a variety of companies. Please contact us to connect with a recruiter and discuss your needs, and follow us on LinkedIn to stay up to date.

Sources:
1. “The State of Talent Acquisition 2023” – Life Sciences Recruitment Report, Industry Insights, 2023.
2. “Navigating the Talent Crunch: Strategies for Recruiting in the Life Sciences Industry” – Biotech HR Trends, Talent Solutions, 2022.
3. “The Rise of External Recruitment Agencies in Life Sciences” – Recruitment Trends and Insights, Biotech Today, 2021.
4. “The Cost of Keeping a Position Open” – Talent Acquisition Insights, Sci.Bio, 2023.

Related Blogs:
The Cost of Keeping a Position Open
Struggling To Fill A Job Vacancy?
A Researcher, a Communicator, or Something in Between? Knowing Who to Hire for Each Role

How to Build Your Professional Network

How to Build Your Professional Network

Author:  Tara Smylie

About one thing, modern psychology is certain: we humans are social creatures. Whether you’re looking to skill up, or take on new projects as a freelancer – don’t underestimate the power of connections!

Below you’ll find some useful tips to help you build a thriving network of connections in your professional life.

1. Social Media Is Your Friend

Intentional outreach on Linkedin is a fabulous place to start. Don’t be scared to pull the trigger and connect with someone you don’t know – especially if you add a short, sweet, and to-the-point note to go along with it.

Joining intentional groups on Linkedin is another great way to meet people in your field. Let’s say you’re a chemical engineer looking to learn more about the management aspect of the life science field. By joining a group of like-minded individuals, you’ll be exposed to a wide variety of perspectives, resources, and ideas that you may never have even thought of.

2. Expand your reach – geographically and topically

You never know who you’re going to cross paths with, and how you might help each other when you do. Though it’s important to know people with similar goals, another key part of building a solid network is finding people different from yourself to connect with. If you’re all bringing the same thing to the table, there’s a limit to how much you can partner with each other and learn from each other.

3. Get out to in-person events

They’re not obsolete yet! There’s nothing quite like in-person connection to get the ball rolling with someone new – and your wheels spinning with new ideas for collaboration. In-person events allow you to gain a sense of someone’s personality more quickly, and to ask questions that you might not feel comfortable asking in an online setting. Often there are activities, workshops, or other focal points of in-person networking events too – so you’ll likely have a career-relevant icebreaker to get the blood flowing.

4. Reach out for assistance

People love being asked for help. It makes them feel important, and builds their confidence in their own skills and reputation. If you’re seeking opportunities to learn something new, are trying to start a new group, or simply desire someone to talk to about your latest career undertakings, don’t hesitate to reach out to someone. Asking for help is a vulnerable thing to do, and will only deepen the connections you have.

And as long as you’re not being pushy about it, don’t worry about being a burden. Before you know it, the shoe will be on the other foot, and it will be the helpers who came through for you that need your assistance.

5. Enroll in a course

What better way to meet others in your chosen field than to learn the same new skills together, at the same time?

Nowadays, it’s trickier than ever to meet people in a school setting – so many offerings are online-only. Of course, it’s possible to connect with classmates online if you’re determined enough – but consider in-person courses first if you’re looking to fast-track the expansion of your network.

In an educational environment, everyone is looking to improve themselves somehow, and to add something new to their lives. This openness to change makes people especially open to new connections, too – so grab the chance to take in-person courses and classes whenever you can.

The Takeaway

If there’s one thing we know about connections, it’s that they lead to more connections. Stay home and think about how great it would be to have a network, and you’ll probably find yourself expanding your circle at a snail’s pace. But choose to leap out of your nest and into the world – even if you have to flail and fumble a little bit – and you’ll come away happier, more fulfilled, and ready to soar into the next phase of your career.

Here at Sci.bio, we work with a variety of candidates from new graduates to experienced executives, and have myriad open roles. We pride ourselves on connecting our highly discerning clients with candidates who fit their specific needs. Check out our job search page to see current openings and follow us on LinkedIn for more information.

Related Blogs:

  1. Why Online Networking Can Make a Difference in a Job Search
  2. How to Build Relationships with Recruiters
  3. Useful Online Courses to Beef Up your Resume
Upcoming FDA Decision Dates (PDUFAs)

Upcoming FDA Decision Dates (PDUFAs)

When you work in an industry as rapidly changing as biotechnology, it’s crucial to stay up to date. Awareness of the FDA’s new drug approval dates is especially crucial: the decisions put forth on these dates can significantly affect the outlook of the companies involved, and these ramifications often reverberate through the industry as a whole.

Read on for a rundown of the FDA’s upcoming decision dates for new drug approvals in the first quarter of 2024.

DATE COMPANY NAME DRUG NAME USE/THERAPEUTIC AREA
01/20/2024 Merck Keytruda (pembrolizumab) Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
01/22/2024 Theratechnologies Tesamorelin F8 Formulation Reduction of excess abdominal fat in adults with HIV who have lipodystrophy
01/23/2024 Heron Therapeutics ZYNRELEF (bupivacaine and meloxicam) Post-Operative Pain
01/24/2024 Liquidia Corporation Yutrepia (treprostinil) Pulmonary Arterial Hypertension (PAH); Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD)
1/26/2024 Defender Pharmaceuticals scopolamine (DPI-386) Motion Sickness
1/31/2024 Sanofi and Regeneron Dupixent (dupilumab) Eosinophilic esophagitis (EoE)
1/31/2024 Vyluma NVK002 Myopia
2/13/2024 Ipsen Onivyde (irinotecan liposome injection) Metastatic pancreatic ductal adenocarcinoma
2/22/2024 Venatorx Pharmaceuticals cefepime-taniborbactam Complicated Urinary Tract Infections (cUTI), including Pyelonephritis
02/24/2024 Iovance Biotherapeutics Lifileucel Advanced Melanoma
02/24/2024 Alvotech AVT02 Inflammatory diseases including rheumatoid arthritis
02/26/2024 Minerva Neurosciences Roluperidone Schizophrenia- Negative Symptoms
3/4/2024 Eyenovia APP13007 Post-operative inflammation and pain following ocular surgery
3/4/2024 Vanda Pharmaceuticals HETLIOZ (tasimelteon) Non-24-Hour Sleep-Wake Disorder (Non-24) in adults
03/08/2024 Viatris and Mapi Pharma Copaxone (Glatiramer Acetate Depot) Relapsed forms of multiple sclerosis (MS)
3/13/2024 Mirum Pharmaceuticals Livmarli (maralixibat) Cholestatic pruritus in patients with progressive familial intrahepatic cholestasis (PFIC)
3/14/2024 Madrigal Pharmaceuticals Resmetirom Nonalcoholic steatohepatitis (NASH)
3/14/2024 Bristol Myers Squibb Breyanzi (lisocabtagene maraleucel) Relapsed/refractory large B-cell lymphoma (LBCL)
3/16/2024 Optinose XHANCE Chronic rhinosinusitis with nasal polyps (CRSwNP)
3/18/2024 Orchard Therapeutics OTL-200 Metachromatic leukodystrophy (MLD)
3/21/2024 Italfarmaco Group Givinostat Duchenne Muscular Dystrophy (DMD)
3/23/2024 Incyte ruxolitinib myelofibrosis, polycythemia vera, and graft vs. host disease (GVHD)
3/26/2024 Merck Sotatercept Pulmonary arterial hypertension (PAH)
3/27/2024 Akebia Therapeutics Vadadustat Anemia in patients with CKD undergoing dialysis
3/27/2024 Esperion NEXLETOL (bempedoic acid) Lowers the level of cholesterol in the blood
3/30/2024 Vertex and CRISPR Therapeutics Casgevy (exagamglogene autotemcel) Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
3/31/2024 Rocket Pharmaceuticals RP-L201 (marnetegragene autotemcel) Leukocyte adhesion deficiency-I (LAD-I)
3/31/2024 Regeneron Pharmaceuticals Odronextamab (REGN1979) Relapsed/refractory follicular lymphoma or relapsed/refractory diffuse large B-cell lymphoma (DLBCL)